University of North Carolina Lineberger Comprehensive Cancer Center researchers have identified a potential way to target a subtype of acute myeloid leukemia (AML) using chimeric antigen receptor (CAR) T-cell therapy, a form ...
Jan 4, 2019
0
2
There is a significant need for new treatments for patients with relapsed acute myeloid leukemia, a rare cancer of the blood that is more common in older adults. UNC Lineberger Comprehensive Cancer Center researchers recently ...
Jan 4, 2019
0
3
Findings from a new study by researchers at the National Cancer Institute (NCI) show that patients treated with chemotherapy for most solid tumors during 2000-2014 experienced an increased risk of therapy-related myelodysplastic ...
Dec 20, 2018
0
6
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.
Dec 11, 2018
0
29
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).
Dec 8, 2018
0
138
A study of more than half a million blood samples has allowed scientists to pinpoint the risk factors for a rare type of leukaemia, enabling them to predict if someone will develop the disease eight years before symptoms ...
Dec 4, 2018
0
12
At the American Society of Hematology (ASH) Annual Meeting, Cleveland Clinic medical hematologist and oncologist Aziz Nazha, M.D., will present results of a personalized prediction model that surpassed current prediction ...
Dec 3, 2018
0
1
Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.
Nov 29, 2018
0
4
Researchers from the Princess Máxima Center for Pediatric Oncology have shown that the number of mutations in healthy and leukemic blood stem cells does not differ. Rather, the location of DNA mutations is relevant. Using ...
Nov 29, 2018
0
8
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients ...
Nov 28, 2018
0
72
